Diluted EPS is adjusted by the effect of dilutive securities, including options and awards under the Company’s equity compensation plans, warrants and ESPP. As a result of the Company’s net loss incurred for the three and six months ended June 30, 2025 and 2024, all potentially dilutive instruments outstanding would have anti-dilutive effects on per-share calculations. Therefore, basic and diluted net loss per share are the same for the three and six months ended June 30, 2025 and 2024 as reflected below.


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Numerator:
Net loss	$	(13,548)	$	(2,745)	$	(36,478)	$	(15,573)
Denominator:
Weighted-average number of common shares – basic and diluted	99,326,701		90,911,626		97,422,458		82,263,168






Loss per common share – basic and diluted	$	(0.14)	$	(0.03)	$	(0.37)	$	(0.19)

(a)For the three and six months ended June 30, 2025 and 2024, outstanding stock options of 7,186,867 and 6,438,239 to purchase shares of Common Stock, respectively, were anti-dilutive.

(b)For the three and six months ended June 30, 2025 and 2024, outstanding restricted stock units of 5,156,701 and 3,935,201 to purchase shares of Common Stock, respectively, were anti-dilutive.

(c)For the three and six months ended June 30, 2025 and 2024, outstanding warrants of 2,910,548 and 4,624,977 to purchase shares of Common Stock, respectively, were anti-dilutive.